The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. On March 27, 2017, STAT published a report by Adam Feuerstein stating that Geron’s recent stock gains were due to “flimsy” claims regarding the efficacy of imetelstat, Geron’s experimental treatment for myelofibrosis. The report states that available data for imetelstat undercuts Geron’s representations as to the drug’s efficacy. When the truth was revealed to the investing public, shares of Geron fell $0.83 or over 13% to close at $5.15 per share on March 27, 2018. Geron shares continue to fall sharply during intraday trading on March 28, 2018, causing shareholders harm.